Xiao-Nan Hao

Xiao-Nan Hao

Auto-generated profile, based on publicly available information

Xiao-Nan Hao

Peking University Sixth Hospital Peking University Institute of Mental Health NHC Key Laboratory of Mental Health (Peking University) National Clinical Research Center for Mental Disorders (Peking University Sixth Hospital) Beijing China

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2025 in Depression and Anxiety
Verified
Journal Article
Open access
SWSanwang Wang
Sanwang Wang
WMWeifeng Mi
Weifeng Mi
XHXiao-Nan Hao
Xiao-Nan Hao
XLXiaoxing Liu
Xiaoxing Liu
XWXin Wen
Xin Wen
LLLin Lu
Lin Lu
Toludesvenlafaxine hydrochloride sustained‐release tablets, as China’s first independently developed chemical Class 1 innovative drug with independent intellectual property rights for the treatment of depression and a new molecular entity, represent a novel triple reuptake inhibitor (TRI) with specific target selectivity for serotonin (5‐HT), norepinephrine (NE), and dopamine (DA). This single‐arm, multicenter clinical study aimed to evaluate the efficacy and safety of toludesvenlafaxine in alleviating anhedonia symptoms in patients with major depressive disorder (MDD). A total of 123 patients aged 18–65 years were enrolled between April 2023 and April 2024 and received an 8‐week treatment with toludesvenlafaxine sustained‐release tablets (80–160 mg/day). The primary efficacy endpoint was the change in the total score of the Dimensional Anhedonia Rating Scale (DARS) at weeks 2, 4, and 8. Significant improvements in DARS scores were observed, with mean changes from baseline of 8.4 (95% CI [6.4, 10.4], p < 0.0001), 14.1 (95% CI [12.0, 16.2], p < 0.0001), and 20.4 (95% CI [18.0, 22.9], p < 0.0001), respectively. Additionally, after 8 weeks of treatment, plasma levels of neurotrophic factors, including mature brain‐derived neurotrophic factor (mBDNF) ( t = 28.78, p < 0.0001), pro‐BDNF ( t = 27.71, p < 0.0001), and vascular endothelial growth factor (VEGF) ( t = 31.07, p < 0.0001), were significantly increased, and the plasma level of IGF‐1 was not significantly changed ( t = 0.35, p = 0.7269). No association was found between the percentage of changes in neurotrophic factors and the percentage of symptom improvements. Toludesvenlafaxine was generally well‐tolerated, with treatment‐emergent adverse events (AEs) (TEAEs) reported in 83.7% of participants and treatment‐related AEs (TRAEs) in 76.4%. These findings indicate that toludesvenlafaxine hydrochloride sustained‐release tablets are safe, well‐tolerated, and effective in alleviating anhedonia symptoms in patients with depression. Trial Registration: http://www.chictr.org.cn (No.: ChiCTR2300070331).

17 December 2025 in General Psychiatry
Verified
Journal Article
Open access
YSYifeng SHEN
Yifeng SHEN
XHXiaonan Hao
Xiaonan Hao
XSXiaoning Shi
Xiaoning Shi
ZTZhiping Tao
Zhiping Tao
XYXueqin Yu
Xueqin Yu
HZHongyan Zhang
Hongyan Zhang
Background: GW117 (N‐(2‐(6‐chloro‐7‐deuteromethoxy‐naphthalen‐1‐yl) ethyl) acetamide) is a dual‐acting agent (MT1/MT2 agonist, 5‐HT 2C antagonist) with prior evidence of antidepressant efficacy and favourable safety. Aims: To preliminarily evaluate the efficacy and safety of GW117 in major depressive disorder (MDD) and to explore the optimal dosing. Methods: A total of 280 eligible patients aged 18–65 years with MDD were randomly assigned (1:1:1:1) to 8 weeks of double‐blind treatment with fixed doses of GW117 tablets (20, 40, 60 mg/day) or placebo. The primary endpoint was the change from baseline to Week 8 in the total score of the Hamilton Rating Scale for Depression‐17 item (HAMD‐17). Key secondary endpoints included changes in the Montgomery‐Åsberg Depression Rating Scale (MADRS) total score over the same period. Results: In the full analysis set (n=276), GW117 showed numerically greater reductions versus placebo in the HAMD‐17 and MADRS total scores, as well as higher response rates at Week 8. However, these differences did not reach statistical significance, potentially due to a high placebo response and other contributing factors. In a post hoc analysis of an optimal subgroup (baseline HAMD‐17 >24 or insomnia factor >4), GW117 showed efficacy in improving multidimensional symptoms, including insomnia. The 20 mg dose demonstrated a significant 3.66‐point greater reduction in MADRS (p=0.026) and a 23.16% higher response rate (p=0.013) compared with placebo. GW117 was well‐tolerated, with no cases of alanine aminotransferase or aspartate aminotransferase exceeding 3× the upper limit of normal and no concerning safety signals reported. Conclusions: This exploratory study found that GW117 demonstrated encouraging antidepressant efficacy and a favourable safety profile in patients with MDD. Although differences versus placebo did not reach statistical significance in the overall population, GW117 20 mg monotherapy showed significant improvements in multidimensional depressive symptoms, including insomnia, in the optimal response subgroup. No hepatotoxicity was reported, supporting its promising therapeutic potential for further clinical development. Trial registration number: NCT06796868 . Date of retrospective registration: 23 April 2025